Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates

Journal: Journal of Clinical Investigation

Published: 2018-07-17

DOI: 10.1172/jci97117

Affiliations: 15

Authors: 21

Go to article
Institutions FC
Department of Translational Hematology and Oncology Research (THOR), Cleveland Clinic, United States of America (USA) 0.38
Karyopharm Therapeutics Inc., United States of America (USA) 0.10
Department of Hematology and Medical Oncology, Cleveland Clinic, United States of America (USA) 0.10
Department of Quantitative Health Sciences (QHS), Cleveland Clinic, United States of America (USA) 0.05
Affiliated Hospital of Weifang Medical University, China 0.05
Department of Pathology, Cleveland Clinic, United States of America (USA) 0.05
Department of Pathology, CWRU, United States of America (USA) 0.05
Institute of Hematology, University of Perugia, Italy 0.05
Azienda Ospedaliera di Perugia, Università degli Studi di Perugia, Italy 0.05
Finsen Laboratory, Rigshospitalet, Denmark 0.02
Faculty of Health and Medical Sciences, UCPH, Denmark 0.02
Biotech Research and Innovation Centre (BRIC), UCPH, Denmark 0.02
Danish Stem Cell Center (Danstem), UCPH, Denmark 0.02
KU Department of Internal Medicine, United States of America (USA) 0.02
KU Cancer Center, United States of America (USA) 0.02

Return